Pharmaceuticals, Biotechnology and Life Sciences
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of…
Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2%…
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including…
The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22…
First subcutaneous anti-CD38 therapy to demonstrate potential to prevent end-organ damage, and extend progression-free survival and overall survival based on…
Media ReleaseCOPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and…
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease…
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies…
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity…